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Abstract: Twin-screw granulation (TSG) is a pharmaceutical process that has gained increased
interest from the pharmaceutical industry for its potential for the development of oral dosage forms.
The technology has evolved rapidly due to the flexibility of the equipment design, the selection of
the process variables and the wide range of processed materials. Most importantly, TSG offers the
benefits of both batch and continuous manufacturing for pharmaceutical products, accompanied by
excellent process control, high product quality which can be achieved through the implementation of
Quality by Design (QbD) approaches and the integration of Process Analytical Tools (PAT). Here,
we present basic concepts of the various twin-screw granulation techniques and present in detail
their advantages and disadvantages. In addition, we discuss the detail of the instrumentation used
for TSG and how the critical processing paraments (CPP) affect the critical quality attributes (CQA)
of the produced granules. Finally, we present recent advances in TSG continuous manufacturing
including the paradigms of modelling of continuous granulation process, QbD approaches coupled
with PAT monitoring for granule optimization and process understanding.
Keywords: twin-screw granulation; granulation mechanisms; PAT tools; QbD; continuous processing
1. Introduction
Granulation is a well-known powder processing technique, used in the pharmaceutical
industry for the manufacturing of solid dosage forms [1]. This term is used to describe the
processing of powders for particle enhancement with the aim to improve a range of proper-
ties such as flowability, compressibility, tabletability and the homogeneous distribution of
active ingredients, etc. [2,3]. The transformation of powders to agglomerated particles is
usually performed prior to tableting to ensure minimal aggregation and a uniform flow
of processing material from the feeding hooper, and good compressibility in the tablet
dies [2]. Typically, granulation is a particle size enlargement process where particles are
processed to form larger multi-unit entities with uniform distribution ranges, from smaller
sized granules with a distribution in between 0.2–0.4 mm, to larger sized granules with
(around 1–4 mm) typically prepared for capsule manufacturing [4,5]. Depending on the
final particle size, granules are further processed with other excipients and used as an
intermediate before compression to form tablets, or for filling hardened gelatine capsules.
Furthermore, granulation technology is used to reduce the generation of toxic dust during
powder handling [5]. A good quality granule exhibits less a non-friable behaviour and
produces less fines during processing. Pharmaceutical powders often have uneven parti-
cle size distribution leading to segregation during storage which can be minimized and
improve content uniformity via granulation. The bulk powders present several practical
implications such as higher packaging, storage and transportation requirements which can
be tackled through the manufacturing of granules with higher densities.
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In general, pharmaceutical manufacturing can be divided into two distinct stages:
primary manufacturing (i.e., upstream operations), the production of the active ingredient
from the starting reagents, and secondary manufacturing (i.e., downstream operations),
which involves the conversion of the active drugs into products suitable for administration
such as granules, capsules or tablets [6]. The secondary manufacturing involves the
integration of multiple processing units, necessitating an comprehensive understanding of
processing parameters to optimise the formulation [7–9].
The manufacturing of granules can be conducted via three different approaches:
dry, wet and melt granulation. The dry granulation involves the aggregation of primary
powders in the absence of any liquids, under high pressure, to facilitate the bonding
of the particles by direct contact followed by milling to attain the desired size [1]. This
method is suitable for processing moisture sensitive active pharmaceutical ingredients
(APIs), due to the absence of a liquid component. Another benefit to this method is its
cost-effectiveness due to the fewer processing steps, little or no material waste and low dust
exposure. A common approach for dry granulation is roller compaction where powder is
fed into two counter rotating rolls producing flat shaped ribbons of compacted material.
The use a dry binder, such as cellulose, starch or povidone, in the powder blend is essential
to achieve a stronger ribbon [10]. Subsequently, the ribbons can be milled to obtain the
desired granule size. In many cases, the use of roller compaction/dry granulation has been
described as a “continuous production line” [11]. The technique has been frequently used
over the past two decades and has been shown to improve drug dosage weight control,
content uniformity and powder flow, while also being easy to scale up and facilitating
continuous manufacturing [12]. However, this technique does result in greater generation
of fines and requires high forces for compaction, making the technology unsuitable for the
manufacture of certain drugs e.g. processing of highly potent drugs increase the chances
of environmental contamination while poorly compressible drug substances may lead to
sticking on the rollers [13,14].
A wide range of powder processing methods are employed in the pharmaceutical
industry to produce granules with particular characteristics in terms of their physical and
pharmaceutical properties (e.g., bioavailability) [15]. According to several studies, wet
granulation provides better control of drug uniformity, improves flowability and increases
bulk density and porosity [16–18]. Also, volatile and non-toxic solvent (e.g., ethanol,
isopropanol) can be used for the processing of powder blends which are an alternative
for moisture sensitive APIs as they tend to dry quickly. The use of aqueous solution is a
common approach to create strong bonds between the particles that lock them together.
However, when the water dries the powders might break and thus it is a prerequisite to
form a dense mass. Following, the production of granules, further processing is carried
out by sieving, milling or mixing with additional components to manufacture a finished
dosage form. Wet granulation technologies usually involve the use of high shear mixers
and fluidize bed that produce dense and uniform granules.
Theoretically, granule mechanism requires the adhesion of particles for the formation
of agglomerates and comprises of three key steps. The particle adhesion takes in various
steps, as shown in Figure 1. This involves wetting and nucleation, transition and ball
growth [5]. Initially, adhesion or cohesion forces take place through the formation of an
immobile thin layer which results in the decrease of the interparticulate distance while
increasing the contact area though Van der Waals forces. This is the pendular state where
water is distributed as mobile thin layer around the particles holding them together through
lens-shaped rings. The transition state is entered by the further addition of granulating
liquid leading to the formation of stronger liquid bridges (funicular state) by filling up the
interparticulate void space. This is usually the end of the wet granulation process but further
liquid saturation (80%) and air displacement lead to the capillary state where large spherical
granules (ball growth) are built up which are not suitable for pharmaceutical purposes.
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Figure 1. Diagram of granule formation (Reproduced with permission from [19], Elsevier, 2019).
Melt granulation is similar to the dry granulation process, however, the binder solution
is replaced with a meltable binder. Fluidised bed melt and melt extrusion or even high
shear granulations are processing technologies that can be effectively used where the binder
i melted/soften near o above its mel ng point or glass transition temperature in order to
obtain agglomerated granules [20–23]. Usually, the melting point of binders varies between
30–100 ◦C and they either melt or become tacky followed by solidification upon cooling.
In this review, we provide a comprehensive discussion on twin-screw granulation
processing including granulator (extruder) details, the effect of processing parameters on
the granule production followed by the formation mechanisms of the different granulation
approaches. Recent advantages on continuous twin-screw granulation are also presented
alo g with cas studies of QbD, and Process Analytical To ls (PAT) implementation by
various research groups.
2. Instrument tion of a Twin-Screw Granulator (Extruder) (TSG)
Extrusion gran lation equipmen is almost identical to that used for typical H t
Melt Extrusion (HME) and consists of the extruder, auxiliary equipment, downstream
processing equipment and some other monitoring tools for the performance and evaluation
of products [24]. The extruder typically is composed of a feeding hopper, single or twin
screw, barrels, die and driving unit for screw. The auxiliary equipment includes cooling
and heating device connected to the barrels, the conveyer belt to cool down the extrudates
and the solvent delivery pump. The monitoring screen displays screw speed, temperature
scales, torque monitor and pressure scales.
Overall extrusion process in divided into four sections [25]:
- Feeding of the materials
- Conveying of materials ( ixing and particle size reduction)
- Out flow from the extruder (no die)
- Downstream processing
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During processing, the temperature is controlled by electrical heating bands and mon-
itored by thermocouples displayed on monitoring screen. Usually, the extruder comprises
of single or twin rotating screws placed inside the barrel. The barrel is comprised of sections
which are bolted and clamped together and described as zones in the extruder. A die plate
is attached to the end of barrel, which determines the shape of final extruded product
(Figure 2).








































Figure 2. Schematic diagram of an extruder (image was kindly offered by Coperion GmbH).
Currently, the most common extruder types are: (a) the single screw and (b) the Twin
Screw extruders [26]. The single screw extruder consists of only one screw placed in the
extruder barrel whil more advanced twin screw extrusi systems consist of a pair of
screws that rotate in the same direction (co-rotating) or opposite direction (counter rotating).
Usually, the extruder screw is characterised by length/ diameter (L/D) ration of screw
which typically ranges from 20:1 to 40:1.
The heat required (melt granulation) for the melting or fusing of the material is
provided by the c mbination of electric or liquid clams on the barrels and friction of the
materials produced by shear force between rotating screw and barrel wall [27,28].
The extrusion granulation process is fully controlled by applying the optimal tem-
perature, screw speed and feed rate. The technique has a potential to control and process
material at specific r quirements such as high shear extrusion or addition of solvent at
solvent evaporation stage during processing. Screw configuration allows the extruder
to perform mixing and particle size re-arrangement which performs a vital role for the
dispersion of API into carrier matrices.
Th aterial is fed from the hopp r direc ly int the deeper flights r greater fligh s
pitch. The geometry of flights (shown in Figure 3) allows the feeding materials to fall
easily into to rotating screw for conveying alongside the barrel. The helix angle and pitch
of the screw controls the constant rotation speed of screws. The materials are fed as a
solid into the transition zone where it is mixed, compressed, melted and plasticized. The
compression process of materials in the barrel is regulated by either decreasing thread
pitch but maintaining constant flight depth or vice versa [29]. This process creates pressure
as the material moves through the barrel towards the discharge zone. This discharge zone
is similar to these conveying elements, except the channel depth is far greater to allow
for the build-up of more mat rial, to allow for quick discha ge. The material moves in a
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helical path as a result of transverse flow, pressure flow, drag flow and leakage while the
movement of material in barrel is affected by two reverse mechanisms (a) screw diameter
space and (b) width of the barrel. The material reaches the metering zones with uniform
thickness and flowability which drag out the granulated material as a uniform delivery of
granules. The downstream processing is equipped with conveyer which permits extrudates
to cool down to room temperate by applied air pressure.
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Figure 3. Geometry of an extruder screw (Reproduced with permission from [25], Elsevier, 2002).
In twin screw extruders, screws can be rotating either in the same (co-rotating) or
opposite (count r-rotating) direction as shown in Figure 4. Two screws placed into the
barrel side by side and it is designed to control operating parameters such as the filling
level of material, the screw speed, the feed time and the residence time [30]. In a counter
rotating extruder, twin screw rotates in opposite direction in barrel. This type of extruder
is usually applied for high shear materials as mater al squeezed through the g ps betwe n
screws. A counter rotating screw provides an excellent dispersion of blended particles,
however, it also leads to increased air entrapment, high pressure and low output as a result
of the lower maximum screw speed. This type of extruder does not produce a pushing
effect of materials into the barrel due to opposite dir ction of screw rotation, so material
throughput is purely dictated by the feed rate, as powder moves through the counter
rotating screws due to being pushed through by the powder behind it.
On the other hand, a co-rotating screw rotates in the same direction and it has the
advantage of a self-wiping and intermeshing design [25]. This type of extruder is mainly
used in the industry which has competency to operate at high screw speed and provide
excellent high output with intensive mixing and conveying of materials during process.
Co-rotating is sub-classified as non-intermeshing and i termeshing.
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Figure 4. Twin screw co-rotating and counter-rotating screw (reproduced with permission from [31], IOPscience under
Creative Commons Attribution 3.0 licence).
Intermeshing twin screw extruders are very popular as they provide self-wiping to
minimize the non-motion of materials, prevent overheating and display superior mixing
compared to single screw extruders. Intermeshing extruders operate on the principle
of first in/first out where material does not rotate along with screw to barrel [32]. Non-
intermeshing extruders are used to extrude a highly viscous material which is not liable to
cause high torque during processing [33]. This type of counterrotating screw configuration
is more popular in plastic or polymer processing industry, as heating during the operation
substantially reduces torque generation.
3. TSG Processing Parameters
3.1. Temperature
The heating for each zone of t e barrel is niformly and accurately controlled, there-
fore, the process can be run using a single temperature value or a temperature profile,
depending on the specific requirements of the process. Temperature has an effect on
the processability of the formulation, as viscosity is temperature dependent, and also on
the quality of the final product. The bed temperature for lubricated powders varies from
5–15 ◦C and depends on the flow rate, screw speed, L/S ratio and the amount of polymer in
the binding solution [34,35]. The temperature variations within the barrel can easily reach
70 ◦C while the presence of long mixing zones increases the temperature of the formed
granules. The temperature rise in the barrel can be also influenced by the different wetting
behaviour of the processed powders [36]. For example, the high absorption capacity of
microcrystalline cellulose resulted in non-uniform wetting of the solids and prevented
sufficient process lubrication leading to increased frictional heating.
3.2. Screw Design
Screw configuration is designed based on the type, number and sequence of phases a
given processing material requires during manufacture. At the entrance of the extruder,
conveying screw elements of high pitch sizes are placed to ensure proper powder feeding
since bulk density of the inlet materials is much smaller than extrudate density. A standard
configuration presents conveying elements up to two third of the screw length, followed
by high a shear mixing zone. Venting during the extrusion process is sometimes needed to
remove entrapped air or residue moisture from the final product. Venting requires a drop
in pressure in that part of the extruder to prevent the exiting of the material through the
opening. This is achieved through the positioning of high pitch conveying elements in the
barrel area meeting the venting zones.
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The elements on the screw shaft are interchangeable so a customised screw configura-
tion can be assembled to match the specific requirements of each process. Elements differ
in design to suit the various steps of processing, such as transporting, mixing, melting and
shaping. Conveying elements have self-wiping geometry needed for transportation of the
material along the screw, whereas the free volume of the screw and speed is modulated
by pitch size (Figure 5). Mixing (kneading) elements are used for mixing, melting and
homogenisation while they comprised of disc, which are staggered under certain angle.
The angle determines the conveying and mixing properties; conveying properties decrease
whereas mixing properties increase with increasing offset angle. Additionally, longer discs
impart more shear, while shorter improve dispersive mixing. Therefore, kneading elements
can be classified as:
- forwarding (convey polymer to the die)
- neutral (used for either distributive or dispersive mixing)
- reversing (convey polymer flow back toward the feed)




































Figure 5. Co veying elements (a) and mixing elements (b).
Screw configuration has a critical impact on the product properties where insufficient
mixing results in non-homogenous blends or leads to incomplete product conversion or
reaction. On the contrary, if the mixing zone is too long and imparting too much shear,
residence time and temperature can increase, resulting in API degradation.
The use of conveying elements with different flight pitches can have a significant
effect on the extruded granules. By increasing the flight pitch of the screws, the granule
output is increased while the fines are reduced due the larger volume which is available for
the wetted mass [37,38]. The use of higher flight pitch facilitates the formation of porous
granules while the increased number of conveying elements r sults in higher granule
strength. The presence of conveying elements right after a kneading zone plays a key role
as it minimizes the formation of large clumps, resulting into their breakage.
Furthermore, the kneading elements play a key role due to their capability to produce
stronger compressive granules. The Figure 6 show a TSG process illustrating the gran-
ule development and compaction. When using high offset angles of kneading elements
granules appear larger and denser while longer mixing zones produced less friable and
breakable particles with narrow and controllable size.
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Figure 6. oto showing a wet twin-screw granulation (TSG) wet of microcrystalline cellulose/lactose monohydrate mixture
with a kneading block (right most side of the image). The direction of flow is to the right.
To the contrary the usage of multiple kneading zones has a negligible effect on the
granule particle size and distribution. Kneading elements control the morphology of
extruded granules and usually produce elongated shapes compared to spherical shaped
granules obtained when only conveying screws are implemented [39,40].
3.3. Feeding Rate and Screw Speed
The feeding rate is one of the most important process variables and it has been found
to influence the particle size and granule density/strength. High feeding rates are related to
increased compressive forces which correspond to larger, dense granules. In the absence of
kneading zones, high feed rates increase the formation of fines which are friable and easily
break while the liquid distribution in the powder blend is non-uniform. Screw speed is
related to the shear rate in a TSG, but it has a low impact on the particle size of the granules
and the residence time. By increasing the screw speed only a minor size reduction has been
observed and only when high adhesive polymer are used in the granulation blend [41].
3.4. Mixing in a TSG
The powder mixing in a TSG is directly related to the screw configuration and the
resulting shear rate as a function of the process settings. This is classified as radial or axial
based on the direction of spread. During the TSG process radial mixing is a prerequisite
for a homogeneous granule distribution at constant powder feeding while axial mixing
can also help to avoid inhomogeneities. The selection of feeding rate, screw speed and
screw configuration determine the degree of mixing. The axial mixing is directly affected
by the Residence Time Distribution (RTD), screw speed and geometry. When using high
screw speeds, the axial mixing increases as estimated by the rise of the normalized variance
(σ2θ) and the lowering of the Peclet number (Pe). However, there are contradictory studies
suggesting that axial mixing is not affected by the processing parameters [42].
The most favourable feature of a TSG process is the capacity to process high powder
throughput in a short residence time (0–20 s). Despite the possible gains of TSG over batch
manufacturing this is not always straightforward because there is a limited time frame
to achieve homogeneous granule distribution, granule formation and breakage to obtain
the final product. Hence, in order to achieve a high yield, the process should be designed
carefully with longer residence time than the mixing time across the extruder barrel. The
process is more complicated when mixing powders with the granulating liquid which
requires homogeneous liquid distribution within the powder. Sayin et al. observed that
the site of liquid addition and the periodicity of the peristaltic pump has a strong impact
on the moisture content and distribution [43]. The use of more kneading zones can help
to improve the distribution of granulation liquid, but further improvements require the
addition of screw elements with modified geometries that can induce distributive mixing.
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The addition of granulating liquid results in the formation of liquid bridges between
the powder particles and subsequently aggregation takes place to produce larger granules.
The evolution of particle size and the primary shaping mechanism in the TSG is limited due
to the capacity of the extruder. Extensive studies have shown that granule size increases
not only after the kneading zones but also upstream (before) suggesting there are not only
two granule formation mechanism such as the dispersive and distributive mixing. In the
third mechanism the built-up material before the kneading zone (flow restriction) is forced-
mixed with the inbound powder due to the throughput force. As a result, the increase
in the throughput (feeding) lead to the increase of granule size assuming there is enough
granulating liquid to from large agglomerates.
Kumar et al. investigated the interrelations of the residence time and mixing settings
over the quality of extruded granules [44]. The study demonstrated that the increase of
kneading elements had no influence on the yield fraction despite the improvement of
powder mixing and residence time. The same was observed by increasing the L/S ratio
which resulted only in the formation of larger granules.
4. Twin Screw Granulation
TSG is an advanced processing technology that has been extensively used for granules
production over the last couple of decades [45]. Several studies have been reported
relating to TSG optimization by investigating the effect of the formulation composition and
operational variables such as screw configuration, pitch and length of conveying element,
thickness and angle of kneading element, or influence of kneading blocks. A schematic
diagram of a TSG line is illustrated in Figure 7.
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Figure 7. Schematic representation of a twin screw granulator (Reproduced with permission from [46], Elsevier, 2020).
The first study for the development of pharmaceutical granules at a laboratory scale
using a single-screw extruder was reported by Goodhart et al. in 1973 [47]. The investi-
gation was undertaken to evaluate various factors related to wet granulation such as the
effect of granulating fluid, type of end plate, number of mixing anvils and screw speed.
Another objective of these stu ies was to further understand the level of content uniformity
during granulation. The use of water-isopropanol as granulating fluid reduced the sugar
solubility in the granulating fluid, creating increased torque during highspeed process-
ing. The granules prepared by using this granulating fluid resulted in the compression
of less gritty and smoother tablets compared to water. It was concluded that the water-
isopropanol granulating fluid created processing interruption but produced granules with
low bulk densities.
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Later on, in 1986, Gamlen and Eardley introduced the twin screw extruder in phar-
maceutical research, to produce paracetamol extrudates with a combination of excipients
i.e., Avicel, lactose and/ or hydroxypropyl methyl cellulose (HPMC) and using water as
a granulating fluid [48]. The results revealed that addition of HPMC in the formulation
influenced significantly on the extrusion properties. HPMC helped to retain water in its
interstitial spaces, reducing frictional forces between extruder and the plate. Micrographs
of the extruded formulation with and without HPMC showed similar appearances. Hence,
the addition of HPMC improved the extrudability without affecting the extrudate quality.
A year later, Lindberg (1987) and later Kleinebudde (1998) also employed twin-screw
extruders for the formation of effervescent granules [49–54]. Furthermore, TSG has been
implemented to perform dry, wet and melt granulation process [55] including scaling-up of
continuous granulation coupled with Process Analytical Tools (PAT) by applying Quality
by Design (QbD) approaches [56].
Despite the fact the TSG is an emerging technology the majority of the published
studies are data-driven and (semi-) mechanistic which investigate the association between
the process parameters and the granulation performance using multivariate data analysis.
However, the effect of critical processing parameters (CPP) on the growth and kinetics
of granule formation is not well established in comparison to batch granulation (e.g.,
high shear).
For this reason, theoretical [57,58] and experimental [43,59–61] approaches have been
introduced to understand the transport, mixing and the fundamental mechanisms in twin-
screw wet granulation. As shown in Figure 8, the dry powder is fed in the barrel through
the feeding zone while the granulating liquid is added using two nozzles (for each screw).
The granule formation takes place through a combination of capillary and viscous forces
facilitating particle binding in the wet stage. Subsequently, the wet material is distributed,
compacted and elongated in the kneading elements (mixing zone) transforming the particle
morphology from small (microstructure) to large (macro structure) irregular and porous
granules. Other sub -processes such as aggregation and breakage can also take place
during granulation. Eventually, the formed granules leave the discharge zone and are
pneumatically fed in a fluidised bed dryer.
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Figure 8. Screw configuration with 12 kneading disks illustrating the formation of granules in TSG (Reproduced with
permission from [62], John Wiley and Sons, 2017).
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A very interesting study was conducted by Dhenge et al. [63] who replaced the
top metal barrel of the extruder and replace it with an acrylic glass barrel to visualize
the granulation process and identify the possible mechanisms. The authors concluded
that there are five regions of granulation behaviour or finished granules classified as
under-wetted (dry), nuclei, crumb, granules and over wetted or paste. The under wetted
granules were obtained when low amount of granulating liquid was used resulting in
un-granulated material. The nuclei refers to the initial wet mass which comprises of
small granulating liquid amounts and are loosely bound with weak mechanical properties.
The “crumb” denotes again ungranulated or poorly granulated materials which present
different strength depending on the type of used elements (conveying of kneading). To
the contrary, the “granules” are robust consolidated agglomerates which have a similar
behaviour compared to classical granules and can be turned to wetted agglomerates or
paste if additional granulating liquid is added. The study included the use of particle image
velocimetry and discrete element modelling to prove that the feed rate and viscosity greatly
affect the surface velocity of dry materials and wet granules. The actual mechanisms of
granulation have been further investigated and elaborated by published work from other
researchers [61]. These studies provide information on how the processing parameters can
significantly affect the aggregation and breakage mechanisms including the consolidation
of the particles.
Furthermore, modelling approaches, for example, using novel multi-component pop-
ulation balance model have investigated TSG processing by taking into account the rate
processes of aggregation, breakage, liquid addition and consolidation. The linkage of the
granulation mechanism with experimental data were used to develop predictive tools [58].
Kumar et al., introduced conceptual model in order to understand and simulate the resi-
dence time distribution (RTD) for a particular TSG formulation that could be easily adopted
for other excipients [57]. The comparison of the experimental findings and best conceptual
model were used to estimate and predict the influence of kneading elements, stagger angle,
screw speed and powder feed on RTD (Figure 9).










































Figure 9. (a) Granule regime map for TSG using conveying screws, (b) Repr sentation of differ t reas in the screw
channel in 2D and (c) Snapshot showing different areas in the screw channel with surface velocity vectors (Reproduced
with permission from [63], Elsevier, 2013).
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In 2010, Dhenge et al. conducted an empirical study on a twin – screw extruder TSE
with model pharmaceutical formulations focused on the physical properties of the final
granules [42]. The authors investigated the effect of screw speed, powder feed rate and
liquid to solid (L/S) ratio on the residence time and torque which was found to affect
the particle size, the strength, shape and structure of the granules. The most pronounced
effect on granule properties was observed with a L/S ratio of 0.4, showing a monomodal
distribution of granule sizes with a peak around the 1000 µm mark. At higher L/S, the
extra liquid caused an increase in the residence time of material in the granulator, resulting
a reduction of undersized and oversized granules. The granules shape and hence the
flow was improved due to the increased amount of granulating fluid which helped to
achieve stronger liquid bridges between the particles. The powder feed rate influenced
the transition and final state of granule properties such as size, shape, structure, porosity,
strength, and dissolution time. At a low feed rate the residence time became long, resulted
in strong granules with an increased average granule size whereas higher feed rate reduced
the granule size. At a powder feed rate of 3.5 and 5 kg/h, the sphericity of the granules
was found to be increased. The improved sphericity of granule was related to the increased
filling at high powder feed rate which led to increase in shearing forces within the barrel
and turned the processed powder to spherical agglomerates. The surface morphology
of the granules became smooth by increasing the length of the screw while porosity was
decreased. The high feed rate not only increased the granules morphological strength and
stability but also affected the dissolution rates. It was concluded that TSG optimisation is a
complex process, and the granule properties (size distribution, strength and structure) are
affected significantly by the critical processing parameters.
Vercruysse et al. (2012) investigated the operational parameters related to TSG and
their effect on the manufacturing process using theophylline as model API [34]. There
was no significant relationship of screw configuration and screw speed to the granules
morphology, but high number of kneading elements and increased throughput resulted
higher torque during granulation. The high torque raised the temperature in the barrel
which led to reduced number of fines and less friable granules. The binder was found to
be more effective when it was dissolved in the granulating fluid. Increasing the number
of kneading elements yielded denser granules with a longer disintegration time and
dissolution rate. The findings of this work suggested that the granule and tablet quality
can be optimised by adjusting specific process variables. Khorsheed et al. (2017) also
investigated the effect of TSG processing parameters on the powder and granule and
tablet properties using microcrystalline cellulose (MCC) or mannitol C160 [64]. Their study
showed increasing MCC granule size and strength can reduce tabletability and vice versa.
Although, mannitol C160 granules did not affect tabletability, particle size reduction had
shown significant compactibility improvements. They found a correlation between the
yield pressure, plastic and elastic work of the initial powders and changes in tabletability
performance as a result of the granulation process. The authors mentioned that increasing
the strength and size of granules may cause reduction of the tabletability.
The granule structure is closely related to tablet’s quality attributes and it can be
controlled by the selection of appropriate excipients as it was recently reported by
Megarry et al. [65]. Allopurinol granulated formulations prepared by wet granulation
via both twin-screw and high shear processing. By using different mannitol grades (200SD
and 160 ◦C) a polymorphic transition during processing, containing mostly β-mannitol,
was found. The 200SD granules had a needle-shaped morphology with high porosity and
specific surface area, which led to poorer flow properties but higher tablet tensile strength.
Furthermore, 200SD granules presented lower d10 values compared to 160C while the L/S
ratio did not affect the size as it was observed for the 160 ◦C. The study suggested that the
understanding of specific excipient grade and their effect during processing is crucial to
optimise tablet manufacturability.
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Lute et al. (2018) investigated the influence of varying barrel fill levels on the mean
residence time, granule properties and tensile strength of tables using MCC and lactose [66].
They reported that specific feed load or powder feed volume directly affects the granule
size and shape. Increasing fill levels of MCC inside the extruder barrel caused shorter
residence times along with decreased granules size. On the other hand, lactose maintained
its granule size at all fill levels. Again, the usage of a specific pharma excipient and their
processing parameters are crucial parts of the granulation optimisation process.
Twin screw dry granulation is considered more effective for granule manufactur-
ing as it limits heat exposure to only one-barrel zone, much shorter than melt granula-
tion. Lui et al. (2017) studied formulations containing different polymeric binders (AF15,
Kollidon VA 64®, Soluplus®, Kollidon SR®), with glass transition temperature less than
130 ◦C [67]. Granulation of the primary powders with some degree of moisture was found
to be beneficial for processed polymers with high glass transition temperatures. Selected
polymer particles are more prone to soften and flow under frictional forces if their Tg was
closer to the barrel zone temperature in the kneading section. Because of this, the Barrel
temperature is often set to match the Tg of the processing polymer to allow for success-
ful granulation. Screw speed was a major cause for friction heating while the kneading
block offset was only minor in its influence on the granulation process. According to
their results, a higher screw speed tended to increase the particles size, producing bigger
chunks (>3350 µm). Conversely, an increase of moisture content in the excipient resulted in
smaller particle size distribution. So, successful granulation can be achieved by varying
the processing parameters and pre-formulation studies will allow one to quickly optimise
the process.
Ye et al. (2019) used twin screw dry granulation to improve the flow property of mois-
ture sensitive materials [68]. They produced dry granule formulations using four different
APIs processed with KlucelTM, EthocelTM, and magnesium stearate for sustained release. A
Design of Experiment (DoE) was employed to determine the effect of different processing
parameters i.e., screw speed, feeding rate, barrel temperature and screw configuration on
the product properties (flow properties, particle size distribution and dissolution time). It
was revealed that an increased screw speed related to a higher percentage of medium size
granules while a negative correlation was found between the amount of large size granules
and screw speed. This was attributed to the decrease of the mean residence time due to the
high screw speeds and the subsequent reduction of the kneading effect on primary powders
and the formation of smaller granules. Higher feeding rates improved the flow properties
of the powders and decreased angles of repose were obtained. The morphology of granules
affected the powder flow where long stripe shape exhibited poor flowability compared
to round shape particles. Finally, drug release was affected by the binder content in the
granule and presented significant variations i.e., large stronger granules with more binder
showed relatively slow release. On the other hand, small amount soft binder provided
less particle adhesion which resulted in faster disintegration and hence faster dissolution
rates. The continuous processing, simplicity of operation, absence of milling, suggest that
twin-screw dry granulation TSDG is more effective compared to other conventional dry
granulation approaches.
Kallakunta et al. (2019) applied heat assisted dry granulation using a twin screw
extruder to formulate sustained release granules [69]. Granulation feasibility was studied
with different binders (e.g., Klucel™ EF, Kollidon® VA64), sustained release agents (e.g.,
Klucel™ MF, Eudragit® RSPO) and diluents at various drug loads. The processing con-
ditions were below the melting point or glass transition temperature of the formulation
ingredients. They found a size correlation to the binding capacity of the excipient. Formu-
lations with Klucel prepared granules with a size of around 250 µm whereas Kollidon®
VA64 promoted the formation of finer granules related to its own particle size (20 µm).
Hence, the good binding properties of the ingredients in the formulation, facilitated easier
granule formation and larger granule size. On the other hand, formulations consisting of
only Klucel™ MF showed minimal erosion (approximately 5%) over 24 h. The drug release
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was found to be incomplete in these formulations, due to the high viscosity of Klucel™ MF.
However, the excellent binding properties and viscosity of Klucel™ MF resulted in dosage
forms with good matrix integrity, which then became one of the controlling factors for
drug release. Conversely, formulations with Kollidon® VA64 reported to undergo greater
erosion which destabilised the tablet matrix and led fast drug release. In summary, heat-
assisted dry granulation could be applied for continuous twin-screw granulation, which
may ameliorate the process constraints and stability problems in conventional granulation
techniques. However, the careful polymer selection is crucial to achieving the desired
physiochemical properties for the end product.
Unlike wet and dry granulation, melt granulation offers several advantages for pro-
cessing pharmaceutical actives. Twin-screw melt granulation is carried out at higher
temperatures than traditional batch melt granulation and thermoplastic polymers can be
used as binders. This has a clear benefit, considering the limited number of traditional
binders that are suitable for use in conventional granulation processes. The process of twin-
screw melt granulation is also advantageous as it eliminates the need for organic solvents
and water, while it is cost effective and environmentally friendly. As a totally water-free
process, twin-screw melt granulation is suitable for drugs that undergo hydrolysis or
degradation in the presence of water but may not be suitable for some heat-labile API.
Ven Melkebeke et al. (2006) studied twin screw melt granulation for the manufacturing
of immediate release formulation using two grades of polyethylene glycol (PEG 400 and
4000) as a binder [20]. The authors described the importance of granulation temperature
on its dissolution properties. A high yield and fast dissolution rate were obtained only at a
processing temperature near the melting point of PEG. Post granulation characterisations
showed that a homogeneous dispersion of the BCS class II drug within the polymeric
matrix created a micro-environment around the drug particles enhancing the dissolution
rate. The addition of small surfactant amounts (polysorbate 80 or Cremophor) helped to
achieve a complete drug release within 10 minutes. A high drug content required greater
PEG and surfactant content to obtain 100% drug release.
Batra et al. (2017) investigated polymeric binders with high melting points (180 ◦C) for
improving tabletability of APIs using twin screw melt granulation [70]. For the purposes
of the study metformin hydrochloride and acetaminophen were used as active ingredients
and several polymers i.e., hydroxypropyl cellulose, hydroxypropyl methyl- cellulose,
polyvinylpyrrolidone and methacrylate-based polymers, including Klucel® EXF, Eudragit®
EPO, and Soluplus® as binders. The prepared granules demonstrated good tensile strength
during tableting even with polymer concentrations as low as 10% w/w. As the melting
temperature of acetaminophen is below 180 ◦C, its TSG temperature was achieved at 130 ◦C,
and even at that temperature, extruded granules provided acceptable compatibility of
>2 MPa, suggesting that compressed tablets could withstand manufacturing and end-use
stresses during coating, packaging, transportation, and handling. The work demonstrated
that a pool of polymeric binders can be successfully use for twin-screw melt granulation
and further exploited in the future.
Unlike wet or dry granulation, in melt granulation the growth mechanism involves
an additional nucleation mechanism known as immersion or distribution as shown in
Figure 10.
Pharmaceutics 2021, 13, 624 15 of 31






















Soluplus®  or higher  became  smaller  and more  spherical  as  a  function  of  temperature 
whereas a lower binder concentration resulted in larger and more needle‐shaped gran‐


















produce  large  volume  production  at  a  cost  effective  manner  [12,74–76].  The  term 
Figure 10. Nucleation mechanism of melt granulation (Reproduced with permission from [71], Elsevier, 1996).
The mechanism was studied by Monteyne et al. (2016) for the development of im-
miscible drug-binder formulations [72]. They implemented thermal analysis, rheological
characterisation and micr scopic images to reach an in-depth understanding of material
behavio r during agglomeration. They reported that the distribution of the binder in
the immiscible blends caused a double Tg and a clear loss peak in the thermogram. The
binder was found to act as a separate phase favouring efficient binder distribution where
a thin binder layer with restricted mobility is formed on the surface of the primary drug
particles during granulation. Then it is covered by a second layer with improved mobility
when the binder conc ntration is sufficiently high. The granules manufactured with 20%
(w/w) Soluplus® or higher became smaller and more spherical as function of temperature
whereas a lower binder concentration resulted in larger and more needle-shaped granules.
The study showed strong evidence of the binder distribution during TSG which strongly
affected the granule characteristics.
In another study, the same group carried out TSG studies with Soluplus (SOL) and
metoprolol (MTP) or caffeine [73]. I this case, thermal analysis showed only one Tg,
indicating a highly miscible system. A high barrel temperature was used to obtain granules
larger than 500 µm which also showed minimum torque fluctuation during granulation.
Surprisingly, granules prepared with 20% or more binder concentration resulted large
aggregates at processing temperatures <90 ◦C. Prepared granules with caffeine-Soluplus
blends displayed a broad particle size distribution over the different binder concentrations
and was not affected by the process peratures whereas the granule s ze distribution of
the MPT/SOLblends appeared narrower and shifted towards lower particle sizes with an
elevated granulation temperature.
5. Twin Screw Granulation and Continuous Manufacturing
The traditional manufacturing of medicinal products in the pharmaceutical industry
uses batch processing, where every single unit operation is conducted separately. The adop-
tion of continuous manufacturing (CM) from pharmaceutical industry is relatively new
and it takes place in a stepwise manner. On the other hand food, petrochemical, polymer
and oil refining industries have been undertaking CM operations for decades and produce
large volume production at a cost effective manner [12,74–76]. The term “continuous”
means a required process may run for an extended period, with raw material constantly
fed into the process. The pharmaceutical industry has faced many obstacles in attempting
such a continuous production method on a day-to-day basis. The main perceived issue is
the industry’s rigid structure, because of the strict supervision of regulatory agencies such
as the U.S. Food and Drug Administration FDA in the U.S. or the European Medicines
Agency (EMA) in Europe [77–79].
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Despite the fact that there are no regulatory hurdles for implementing continuous
processes pharmaceutical industry needs to reform regulatory framework, pharmaceutical
equipment design and operation. Some pharmaceutical companies plan to convert 70% of
their production lines to continuous manufacturing to allow a more efficient product and
process development as part of the product operation. CM processes are usually operating
at or near steady state which allows a clsosed-loop control of the entire process and thus to
a robust and reliable operation. They usually reach steady state in a few minutes enabling
the application of a true QbD manufacturing approach.
Nevertheless, TSG is an ideal example of such a process that has successfully been
introduced for CM production. Recently, GEA introduced a continuous platform for oral
solid dosage forms which integrates multiple operation units comprising of granulation,
drying and tablet compression. As shown in Figure 11, the process involves the dosing
and mixing of raw materials suing multiple feeders, followed by the high shear granulator
for mixing, wetting and granulation through the coupling with a highly accurate dosing
system (e.g., water, solvents, binder solutions). Subsequently the granules are continuously
transferred (e.g., vacuum or gravity) to a fluidized bed dryer for drying and milled to
achieve the desired particle size and content uniformity. The drying process is monitored
with an on-line moisture LightHouseTM probe. Prior to tablet compression in a rotary tablet
press the dried powders are blended with the external phase (e.g., lubricants, disintegrants,
fillers). The tablet press comprises of 6 compression modes such as compression to equal
porosity, Exchangeable Compression Module with a wash-off-line capability which are
coupled with advanced in-line PAT sensors and a control system. The technology is






















Figure 11. ConsiGmaTM continuous high shear granulation process by GEA Group (images provided
by the manufacturer).
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A similar processing technology known as Modular Continuous System MODCOS
has been developed by Glatt for the conversion of the batch mode to a continuous fluid
bed system. As shown in Figure 12, loss in weight feeders is used for the dosing of the
active drug substance and excipients through vacuum conveyor in a twin-screw extruder to
produce medium to high density granules. The wet granules are pneumatically conveyed
into the process insert of the fluid bed via a specially designed transfer line, where they
are continuously dried to the required moisture level. Before the granules are compressed
in tablets with other ingredients a dry mixer is used to achieve homogeneous mixing.
A key advantage of the MODCOS line is the narrow retention time distribution during
drying while a sophisticated discharge system facilitates complete emptying of the process
chambers and thus preventing any cross-contamination with consistent product quality.
The continuous line is coupled with a range of PAT tools including two Near–Infrared
(NIR) probes for determine content uniformity at the end of the extruder or the discharge
system. A moisture probe is used at the fluid bed dryer discharge point and a particle sizer
probe is inserted at the powder discharge points (feeders).
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Figure 12. MODCOS continuous high shear granulation process by Glatt (images provided by the
manufacturer).
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A unique feature of the continuous line is the intelligent control system where all the
process parameters are controlled together and continuously monitored to provide the
basis for automatic process control. The manufacturing process is controlled by recipes
which include the distribution of residence times while the data for all process unit can be
displayed as tables of graphs.
In batch manufacturing of solid dosage form there is a limited process understanding
and control which requires the application of more intensive and advanced manufacturing
processes. Continuous granulation processing is fully automated and thus scale up issues
related to batch manufacturing are no longer encountered. Often, in batch granulation, the
active substances tend to agglomerate especially when they present highly cohesive prop-
erties. This problem can be easily mitigated in continuous granulation by combining high
shear co-milling of the drug substances and excipients followed by low -shear blending.
The powder blends are immediately compressed to produce tablets and, unlike in batch
processing, do not allow time for particles to re-agglomerate. CM lines can be built in a
flexible way for the processing of multiple formulations (products) through careful consid-
eration and optimal design. Continuous granulation lines can be easily adopted for both
dry and wet processing which eventually results a good return on the initial investment.
Other advantages of continuous granulation processing include the following [80]:
- Enhanced development approach by implementing QbD approaches and incorporating
PAT tools
- Reduce risk of manufacturing failure and prevent drug shortages
- Decreased risk of out of specification failures both for intermediates and finished products
- Flexibility by using the same system to develop a manufacturing process
- Effect on supply chain by increasing supply speed and react to market demands
- Agility and reduced scale-up efforts
- Real time quality assurance-secure quality attributes and measure critical quality parameters
- Reduction of capital and operational costs, environmentally friendly
- Cost reductions in R&D, product transfer and productivity
- Reduced system’s footprint
Continuous TSG is an attractive manufacturing process for the development and
commercialization of marketed products. Currently there several commercial products on
the market (small molecules) as shown in Table 1.
Table 1. Marketed products using continuous TSG processing [81,82].
Name Company Disease Year
Orkambi Vertex Cystic fibrosis 2015
Symdeko Vertex Cystic fibrosis 2018
Prezista Janssen Anti-HIV 2016
Verzenio Eli Lilly Advanced breast cancer 2017
Daurismo Pfizer Acute myeloid leukaemia 2018
Lorbrena Prizer Metastatic lung cancer 2018
Tramacet Johnson & Johnson Additive disorder 2017
6. QbD Approaches in Twin-Screw Granulation
The benefits of using QbD approaches in pharmaceutical manufacturing has been
recognized and promoted by regulatory bodies such as the Food and Drug Administration
(FDA) and International Conference on Harmonisation (ICH), combined with PAT princi-
ples and closed loop quality assurance [83–86]. CM lines have been implemented in the
pharmaceutical industry for the manufacturing of the drug product Orkambi by Vertex for
the treatment of cystic fibrosis in 2015. There are only a few studies in literature related to
QbD approaches coupled with PAT tools related to twin-screw granulation.
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The first report was conducted in 2014 by Fonteyene et al., who investigated the effects
of variation in raw material properties on the Critical Quality Attributes (CQAs) of granules
produced by wet granulation followed by tableting [87]. By using a powder-to-tablet wet
granulation line a model formulation of theophylline–lactose–PVP (30–67.5–2.5%) was
investigated while the process parameters were kept steady. For the purposes of the study,
seven grades of theophylline were processed, and the features of granules/tablets were
evaluated. The granule particle size for all experiments showed a bimodal distribution
with granules being in–spec containing either large amounts of fines (>150 µm) or large
amounts of oversized particles (>1400 µm). The differences were directly correlated to the
initial particle size of the theophylline grade. The granules obtained with fine powders
presented higher bulk density and lower tapped density compared to the initial powder
blend suggesting that no tapped volume reduction can be produced when granule powders
have high tapped densities.
As shown in Figure 13, the granule morphology was needle-shaped while for the
small sieve fractions more spherical particles were observed without however been able to
identify any differences for the granules of the various theophylline grades.
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Fi re 13. Pictures of two sieve fractions of the seven granule loads (500–710 µm nd 100 –1400 µm) (Reproduced with
permission from [87], Elsevier, 2014).
Principal Component Analysis (PCA) applied for the content uniformity showed
tha smaller granules present more lactose monohydrate while l rger granules more theo-
phylline. The investigations on the processability showed that theophylline powders
play a key role in feeding with large powders pushing the injectors out of the granulator
barrel. Regarding the tableting process a direct relation between the granule size and
compression forces was observed with small size fractions (<150 µm) r quiring higher
compaction forces.
Maniruzzaman et al. applied a QbD approach by introducing a DoE to investigate
the effect of formulation composition in a wet extrusion granulation process [88]. TSG was
conducted using blends of polymer/inorganic excipients (hydroxypropyl methylcellulose
and magnesium aluminometasilicate-MAS) as carriers and PEG as the binder to produce
Ibuprofen (IBU) granules. The MAS/polymer ratio, PEG amount (binder) and L/S ratios
were set as the independent variable while the dissolution rates, mean particle size (D50)
and the loss on drying (LoD) of the extruded granules as the dependent variables. The mor-
phology of the obtained granules appeared spherical for all processed batches compared
to the needle -shaped IBU with the D50 particle size varying from 100–300 µm. Dynamic
vapour sorption analysis showed a reversible water uptake of all batches and provided
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evidence that the inorganic excipient prevented significant water uptake. The content
uniformity was assessed using Confocal Raman mapping and demonstrated excellent IBU
distribution within the granules which was partially amorphous as a result of the TSG
processing. The DoE analysis revealed that the PEG amounts and the L/S ratio had a signif-
icant effect on both the IBU release and the LoD. The granule particle size distribution was
found to be affected significantly by the MAS/polymer ratios but also the binder amounts.
The same group conducted an identical study using DoE to investigate the effect
of the excipient composition, binder amount and L/S ratio (independent variables) on
drug dissolution rates, median particle size diameter and specific surface area (dependent
variables), as shown in Figure 14 [89]. This time, ethanol was used as granulating liquid
instead of water.
























Figure 14. Response surface plots of Ibuprofen (IBU) release, specific surface area and particle size distribution dependent
variables (Left). Scanning electron microscopy images of (A) bulk IBU, (B) F2 granules (DCPA/Polymer 1.0, Binder 8.0%,
L/S ratio 0.30) and (C) F10 granules (DCPA/Polymer 1.0, Binder 8.0%, L/S ratio 0.30) (Right) Reproduced with permission
from [89], Elsevier, 2017.
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The use of a different liquid resulted in the formation of larger granules with D50
varying from 200–583 µm. For most of the batches, a monomodal particle size distribution
was obtained while the granule morphology appeared spherical as before. This time all
independent variables were found to have a significant effect on the drug dissolution rates
and particle size distribution while the two-way interactions were identified after the data
integration suggested a complex granulation process.
The granule specific surface area was only affected by the MAS/polymer ratios and
the PEG amounts at a significant level. Interestingly, the water insoluble IBU demonstrated
relatively fast release rates within 2 h (pH 1.2) due to the increased amorphous content
which resulted due to the solubilization effect of ethanol and the drug absorption within
the porous network of the inorganic MAS excipient.
Another comprehensive study was conducted by Grymonpré et al., who investigated
the impact of critical process parameters CPP) and critical material parameters (CMP) on
the CQAs in twin-screw melt granulation process followed by milling and tableting of the
formed granules [90]. Two active substances, Acetaminophen (APAP) and hydrochloroth-
iazide (HCT) were co-processed with a range of hydrophilic polymers such as Kollidon
VA64, Soluplus (SOL), Eudragit EPO and Affinisol grades (15 LV, 4M). The processing
temperatures were affected by the glass transition of the binders and, for the HPMC grades
higher temperatures were used due to their complex viscosities.
The milled granules presented lower moisture content (<1%) with a consistent shape
and good flowability. More fines were received when EPO and Affinisol were used as
binders, but overall, all polymers were suitable for melt granulation processing. SOL
and VA64 outperform the rest of the binders due to their high milling efficiency and
resistance to forming fines. Compatibility studies showed identical performance for both
drugs irrespective of the polymeric binder. The tabletability studies (Figure 15) showed
significant improvement of the melt granulated products compared to physical mixtures.
The Tg of the polymer was found to affect the extrusion processing especially for VA64
which resulted in increased torque, while binders with low Tg (e.g., SOL, EPO) facilitated
a smoother granulation process. Similarly, the tableting process was also affected by the
binder grade where EPO showed less fragmentation and higher elastic deformation during
tablet compaction in comparison to SOL and VA64. Overall, the study demonstrated that
twin-screw melt granulation was robust for both low and high drug loading processes and
CQAs were well identified.
In another study, the same group applied a QbD methodology using the continu-
ous ConsiGma® extrusion line to investigate the formulation optimization of twin-screw
granulated composition of various binary filler/binder grades and ratios [91]. By using
multiple linear regression models, the authors were able to understand the impact of the
filler/binder properties on the granule and tablet CQAs. A DoE with 27 batches was
combined with PCA plot to reduce large date sets and identify similarities or differences
of materials with different chemical characteristics. The overall scope of the study was to
identify the impact of materials on CQAs and consequently develop predictive formulation
models with suitable characteristics for the processing of APIs with unfavourable proper-
ties. For example, the study demonstrated that the granule particle size was not affected
by the original particle size or the water uptake of the filler. The granule flowability was
found to be influenced by the binder at higher concentrations but not affected by the filler
properties. The granule friability decreased when PVP was used at higher concentrations.
Finally, the tabletability was not affected by the grade of the filler which showed no impact
at all. To the contrary the binder grade and the use of higher PVP concentrations demon-
strated a significant effect on the improved tabletability. When compared to other binder
grades it was found that the bulk density and specific surface area also plays a role on the
deformation mechanisms, and hence tabletability.
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Figure 15. PC1 vs. PC2 biplot of the determine compaction properties (loadings) for the experimental runs of the DOE
(scores). The numbers represent corresponding experimental run of HCT-EPO formulations (blue triangles), HCTSOL
formulations (dark red circles) and HCT-VA64 formulations (orange boxes), plotted against loadings (star shaped) for which
PF represents the plasticity factor, IER the anti-correlated in-die elastic recovery, PF slope the slope of the plasticity factor
over 4 compaction pressures, Py the heckel value and Db the fragmentation factor. Reproduced with permission from [90],
Elsevier, 2018.
7. Process Analytical Technology (PAT)
PAT are defined as “tools and systems that utilize, analyze and control real-time
measurements of raw and processed materials during manufacturing, to ensure optimal
processing condition are used to produce final product that consistently conforms to
established quality and performance standards” [85]. The goal of PAT is to enhance
understanding of and control the manufacturing in-process, making it consistent with our
current drug quality system. As such, quality cannot be tested into products; it should
either be built-in or by design.
Design space is defined by the CPPs identified from process characterization stud-
ies and their acceptable ranges. These parameters are the primary focus of on-, in-, or
at-line PAT applications [92]. In most cases, spectroscopic techniques, such as Raman spec-
troscopy, UV-Vis spectroscopy and NMR (nuclear magnetic resonance) are commonly used.
Besides the foregoing, near-infrared spectroscopy (NIR) [93], Nano metric temperature
measurement (MTM) [94] and tunable diode laser absorption spectroscopy (TDLAS) are
widely applied tools in the pharmaceutical manufacturing field and play important roles in
real-time monitoring of the processes used. Among these, NIR has drawn great attention in
the industry because it is a rapid, non-invasive analytical technique and there is no need for
extensive sample preparation [95–98]. Typically, it is used for the identification and charac-
terization of raw materials and intermediates, analysis of dosage forms manufacturing and
prediction of one or more variables in the process line or the final product stream(s) on the
basis of on-line, in-line or at-line spectroscopic measurement [99]. The increasing interest
in QbD combined with tools DoE, PAT and risk assessment approaches, has transformed
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pharmaceutical processes from and been adopted by pharmaceutical industry in order to
address quality, manufacturing issues.
The framework of PAT is intended to support the innovation and efficiency in phar-
maceutical processes manufacturing and quality assurance [100]. This includes systems
that can be employed to design, analyse and control manufacturing by measuring critical
quality and performance attributes in a timely manner. This involves measurements of
raw and in-process materials aiming to ensure the quality of the finished products. PAT is
not only a way to implement real-time release testing but also to effectively detect failures
and help understanding the manufacturing processes. Due to the versatility of PAT tools,
relevant information can be obtained by monitoring a range of physical, chemical and
biological attributes. This can be achieved mainly by four key components which include:
- Multivariate tools for design, data acquisition and analysis which help to build scientific
understanding but also to identify CPPs and critical material attributes (CMAs) which
eventually leads to process understanding while the generated information is integrated
into the process control.
- Process analytical chemistry tools can effectively provide real-time and in situ data for
the processed materials and process. The process measurements can also be near real
time (e.g., on-, in and at-line) in invasive or non-invasive manner.
- Process monitoring and control involves the design of process controls and devel-
opment of mathematical relations that provide adjustments to achieve control of all
critical attributes.
Continuous process optimization and knowledge management relates to data collec-
tion and analysis from generated databases over the life cycle of the finished product.
Process Analytical Technology (PAT) in Extrusion Granulation
PAT tools have been successfully implemented in continuous wet granulation pro-
duction lines, namely ConsiGma® developed by GEA Pharma [101]. The process consists
of 5 locations where the critical quality attributes are measured. The first and the third
measure the blend uniformity of the processed powders and the moisture content of the
dried granules while the second monitors the moisture distribution of the formed granules.
A NIR sensor is coupled to the 1st location to allow accurate control of the pow-
der feeding and blending and if possible to provide feedback for controlling blending
operations [102–106]. Similarly, NIR probes were used to measure the moisture content
and distribution.
Fonteyne et al. introduced a combination of PAT tools using Raman, NIR and photo-
metric imaging technique for the evaluation of the powder-to-tablet ConsiGma® production
line [102]. The aim of the study was to acquire solid-state information and granule size
distribution data and in turn use them to predict a range of granule properties such as
moisture content, bulk/tapped density and flowability. As shown in Figure 16 the Raman
and NIR spectra were collected to apply PCA and determine whether the formed gran-
ules contained theophylline monohydrate. Similarly, a PC plot was used to analyse all
data collected through 11 DoE experiments when using the FlashSizer 3D process for the
estimation of granule size and particle distribution.
The same group conducted a separate study in order to obtain an in-depth under-
standing of the twin-screw extrusion granulation and fluidise-bed drying processes using
Batch Statistical Process Monitoring (BSPM) principles [106]. For the purposes of the study,
the group implemented multivariate data analysis in terms of PCA, Partial Least Squares
regression (PLS) and their various extensions such as multiblock PCA/PLS and orthogonal
PLS. The work demonstrated how multivariate data analysis can be routinely used to
generate data from the variable, monitored by the univariate sensors for a continuous
granulation process and how the BSMP concepts are used to monitor variables in order to
identify operational variations.
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Figure 16. ) Raman spectra: PC 1 (47.12%) versus PC 2 (26.95%) scores plot, (b) Raman sp ctra: PC 2 (26.95%) versu PC 3
(16.24%) scores plot, (c) Raman spectroscopy: PC A loadings plots of PC 1, PC 2, and PC 3, (d) NIR spectroscopy: Second
derivative of NIR spectra. Coloured applied as above for Cluster A (dashed line) and Cluster B (full line) (Reproduced with
permission from [101], Elsevier, 2012.
Madarász et al. studied real-time feedback control of twin-screw wet granulation
using dynamic image analysis [107]. In a typical granulation process of lactose and starch
blends a process camera was coupled with image analysis to monitor the particle size
distribution of the obtained granules. The real-time feedback control was implemented by
controlling the feeding rate of the granulating liquid (fed into the TSG through a peristaltic
pump) through a PC.
As shown in Figure 17 the image analysis software consisted of three main stages:
a. Pre-processing: Greyscale filter, Binarization.
b. Post-processing: Excluding particles on the edges of the image, Edge detection, Remov-
ing noise.
c. Analysing and classification: Particle count, Determining particle characteristics (mini-
mum and m ximum calliper diameter, aspect ratio), Classificatio , Summariz tion.
The peristaltic pump is controlled through the image analysis softwa e by a manual
RPM or an auto mode (Figure 18) where the software controls the pump’s rotation speed
via a P controller. By setting the desired granule particle size (e.g., D50: 1200 µm) the
granulation process was tested by simulating different events including system start up
a d pump malfunction. Eventually the system could automatically adjust the granule
particle size at the predefined value.
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Figure 17. Stages of image processin : (a) Raw ima e; (b) Pre-processing; (c,d) Post-processing (Reproduced with permission
from [108], Elsevier, 2018.
















Figure 18. User interface of the developed Online Image Analysis software. (a) Current picture being analysed (b) Dv10,
Dv50 and Dv90 over time (c) Particle size distribution (d) Current Particle size and Average Diameter (e) Control Panel for
the peristaltic pump.
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In-line monitoring via image analysis was carried out by Sayun et al., who used a TSG
with two different screw configurations and various L/S ratios [107]. The real-time high
speed imaging system featured a red-green-blue light that targeted the sample creating 3D
images with a capability to record particles size distributions ranging from 50–3000 µm.
The work revealed that the increase in the fraction of fines corresponded to the L/S ratio in
both screw configurations.
It was also found that the screw configuration imparts a strong effect on granule
porosity while increases in L/S ratio results in decreasing porosity. The authors observed
that the small window of imaging (Figure 19) for capturing granule particles resulted
in measurement fluctuations originated from powder and liquid feeding methods. The
recorded d10 values presented less variations compared to d50 and d90 but were prone to
L/S variations.













































Figure 19. epres ntative images c ptured during experiments using 7KE90 configuration at L/S ratio of 0.15 (a), 0.25 (b),
0.30 (c) (Reproduced with permission from [109], Elsevier, 2018).
Rehrl et al. introduced the concept of using a soft PAT sensor in order to control
thre ifferent continu us processing lines such as HME, direct compression and w t
granulation [109]. By measuring the concentration of the API at specific locations using
NIR probes (for example, directly after granulation) it was able to predict the concertation
of the drug in the feeder. The concentration prediction from on-line spectral measurements
(at specific regions) could be done by constructing calibration curves at various w/w %
and combined PLS regression models. The developed PLS model had a R2 of 98.3% for
the validation experiments carried out at flow rates of 10–20 Kg/h. These experiments
revealed the dependence of the wet granulation process on the feeder excitation.
8. Conclusions
Even though twin-screw granulation is a relatively new process in the pharmaceutical
industry, it represents an excellent paradigm of pharmaceutical processing that combines
principles of QbD and PAT monitoring for process and quality control, while allowing for
continuous manufacturing. The flexibility in terms of screw configuration, temperature
profiles, feeding site of granulating liquid, produced yield and downstream processing
renders TSG advantageous in comparison to conventional granulation processes. How-
ever, there is still a lack of dequate associ tion between the experime tal findings and
theoretical prediction regarding material transport and kinetics in twin-screw granulation.
Nevertheless, TSG is one of the few pharmaceutical processes that has proved its potential
and applicability for the commercialization of finished products through the implementa-
tion of c ntinuous manufacturing. The existing markete pro ucts pave the way fo the
further exploitation of TSG and the development of novel drug formulations.
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